HIV Prevention, Cost-Utility Analysis, and Race/Ethnicity: Methodological Considerations and Recommendations

Medical Decision Making

Volumn 24, Issue 2, 2004, Pages 181-191

  Holtgrave, David R ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Acquired immunodeficiency syndrome; Cost and cost analysis; MESH headings: HIV; Primary prevention

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYTIC METHOD; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; ETHNOLOGY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; RACE DIFFERENCE; UNITED STATES;

CONTINENTAL POPULATION GROUPS; COST-BENEFIT ANALYSIS; ETHNIC GROUPS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; SOCIAL CLASS; UNITED STATES;

EID: 1642336778     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X04263342     Document Type: Article

References (58)

1. Centers for Disease Control and Prevention. HIV/AIDS Update: A Glance at the HIV Epidemic, Atlanta, GA: Centers for Disease Control and Prevention; 2001,
2. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science. 1991;253:37-42,
3. Centers for Disease Control and Prevention. HIV and AIDS-United States, 1981-2000. MMWR. 2001;50:430-4.
4. US Census Bureau. Statistical Abstract of the United States: 2000. 120th ed. Washington (DC): US Census Bureau; 2001.
5. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report: US HIV and AIDS Cases Reported through December 2000. Vol. 12, no. 2. Atlanta (GA): Centers for Disease Control and Prevention; 2001.
6. Anderson RN. Death: leading causes for 1999. National Vital Statistics Reports. 2001;49:11.
7. Centers for Disease Control and Prevention. On the Front Lines: Fighting HIV/AIDS in African-American Communities. Atlanta, GA: Centers for Disease Control and Prevention; 1999.
8. Office of Minority Health, Department of Health and Human Services. Health disparities. Available from: http://www.omhrc.gov/ omhhome.htm
9. Centers for Disease Control and Prevention. Compendium of HIV Prevention Interventions with Evidence of Effectiveness. Rev. ed. Atlanta (GA): Centers for Disease Control and Prevention; 1999.
10. Mize SJS, Robinson BE, Bockting WO, Scheltema KE. Meta-analysis of the effectiveness of HIV prevention interventions for women. AIDS Care. 2002;14:163-80.
11. Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998.
12. Pinkerton SD, Holtgrave DR, Jemmott JB. Economic analysis of an HIV risk reduction intervention for male African American adolescents. J Acquir Immune Defic Syndr. 2000;25:164-72.
13. Sweat M, O'Donnell C, O'Donnell L. Cost-effectiveness of a brief video-based HIV intervention for African American and Latino sexually transmitted disease clinic clients. AIDS. 2001;15:781-7.
14. Holtgrave DR, Valdiserri RO, West GA. Quantitative economic evaluation of HIV prevention and treatment services: a review. Risk: Health, Safety & Environment. 1994;5:29-47.
15. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. A review of the cost-effectiveness of interventions to prevent sexual transmission of HIV in the United States. AIDS Behav. In press.
16. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS. 2001;15:917-28.
17. Kaplan EH. Economic evaluation and HIV prevention community planning: a policy analyst's perspective. In: Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998. p 177-93.
18. Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. Am J Public Health. 1996;86:1442-5.
19. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO, eds. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York: Oxford University Press; 1996.
20. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford University Press; 1999.
21. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
22. Pinkerton SD, Holtgrave DR. A method for evaluating the economic efficiency of HIV behavioral risk reduction interventions. AIDS Behav. 1998;2:189-201.
23. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-90.
24. Holtgrave DR, Qualls NL, Graham JD. Economic evaluation of HIV prevention programs. Ann Rev Public Health. 1996;17:467-88.
25. Holtgrave DR. Setting priorities and community planning for HIV prevention programs. AIDS Public Policy J. 1994;9:145-51.
26. Institute of Medicine, Committee on HIV Prevention Strategies in the United States. No Time to Lose: Getting More from HIV Prevention. Washington (DC): National Academy Press; 2001.
27. Pinkerton SD, Holtgrave DR. Assessing the cost-effectiveness of HIV prevention interventions: A primer. In: Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998. p 33-43.
28. Pinkerton SD, Abramson PR. Evaluating the risks: a Bernoulli process model of HIV infection and risk reduction. Eval Rev. 1993;17:504-28.
29. Weinstein MC, Graham JD, Siegel JE, Fineberg HV. Cost-effectiveness analysis of AIDS prevention programs: concepts, complications, and illustrations. In: Turner CF, Miller HG, Moses LE, eds. AIDS: Sexual Behavior and Intravenous Drug Use. Washington (DC): National Academy Press; 1989.
30. Pinkerton SD, Abramson PR. The Bernoulli-process model of HIV transmission: applications and implications. In: Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998. p 13-32.
31. Family Health International. AVERT: A Tool for Estimating Intervention Effects on the Reduction of HIV Transmission [manual and software]. Arlington (VA): Family Health International; 1998.
32. Kaplan EH. Modeling HIV infectivity: must sex acts be counted? J Acquir Immune Defic Syndr. 1990;3:55-61.
33. Whittington D, MacRae D Jr. The issue of standing in cost-benefit analysis. J Policy Anal Manage. 1986;5:665-82.
34. Williams A. The "Fair Innings Argument deserves a fairer hearing! Comments by Alan Williams on Nord and Johannesson. Health Econ. 2001;10:583-5.
35. Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference subgroups in cost-effectiveness analysis. Health Econ. 2001;10:317-24.
36. Reinke WA. A multi-dimensional program evaluation model: considerations of cost-effectiveness, equity, quality and sustainability. Can J Program Eval. 1999;14:145-60.
37. Ubel PA, DeKay ML, Baron J, Asch DA. Cost-effectiveness analysis in a setting of budget constraints: is it equitable? N Engl J Med. 1996;334:1174-7.
38. Chadwick R, Levitt M. When drug treatment in the elderly is not cost-effective: an ethical dilemma in an environment of healthcare rationing. Drugs Aging. 1995;7:416-9.
39. Pinkerton SD, Johnson-Masotti AP, Derse A, Layde PM. Ethical issues in cost-effectiveness analysis. Evaluation and Program Planning. In press.
40. Gorsky RD. A method to measure the costs of counseling for HIV prevention. Pub Health Rep. 1996;111 Suppl 1:115-22.
41. Kalichman SC, Rompa D, Cage M, et al. Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. Am J Prev Med. 2001;21:84-92.
42. Pinkerton SD, Holtgrave DR, DiFranceisco, Stevenson LY, Kelly JA. Cost-effectiveness of a community-level HIV risk reduction intervention. In: Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998. p 243-59.
43. Holtgrave DR, Kelly JA. The cost-effectiveness of an HIV prevention intervention for gay men. AIDS Behav. 1997;1:173-80.
44. Pinkerton SD, Holtgrave DR, Valdiserri RO. Cost-effectiveness of HIV prevention skills training for men who have sex with men. AIDS. 1997;11:347-57.
45. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the U.S. J Acquir Immune Defic Syndr. 1998;18 Suppl 1;S133-8.
46. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54-62.
47. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. J Acquir Immune Defic Syndr. 2000;25:115-23.
48. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr. 2001;28:124-31.
49. Kleeberger CA, Phair JP, Strethdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82-92.
50. Laws MB, Wilson IB, Bowser DM, Kerr SE. Taking antiretroviral therapy for HIV infection: learning from patients' stories. J Gen Intern Med. 2000;15:848-58.
51. Centers for Disease Control and Prevention. Estimated life expectancy at birth in years, by race and sex: death-registration states, 1900-28, and United States, 1929-97. National Vital Statistics Report. 1999;47:32-3.
52. Gold M, Franks P, Erickson P. Assessing the health of the nation: the predictive validity of a preference-based measure and self-rated health. Med Care. 1996;34:163-77.
53. Cykert S, Joines JD, Kissling G, Hansen CJ. Racial differences in patients' perceptions of debilitated health states. J Gen Inter Med. 1999;14:217-22.
54. Andersen RM, Mullner RM, Cornelius LJ. Black-white differences in health status: methods or substance? Milbank Q. 1987;65 Suppl 1:72-99.
55. Baron J. Does decision analysis have a race problem? J Gen Intern Med. 1999;14:260-1.
56. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994;14:259-65.
57. Russell LB, Sisk JE. Modeling age differences in cost-effectiveness analysis. Int J Technol Assess Health Care. 2000;16:1158-67.
58. Sheldon TA, Smith PC. Equity in the allocation of health care resources. Health Econ. 2000;9:571-4.